Skip to main content

Erik C. von Rosenvinge, MD

Academic Title:

Associate Professor

Primary Appointment:

Medicine

Additional Title:

Chief of Gastroenterology, VA Maryland Health Care System

Location:

UMMC, N3W62

Phone (Primary):

(410) 328-7244

Fax:

(410) 328-8315

Education and Training

B.S., Biochemistry, University of Maryland at College Park, 1995

M.D., New York University School of Medicine (AOA), 1999

Internship and Residency in Internal Medicine, David Grant USAF Medical Center, Travis AFB, CA / UC Davis Medical Center, Sacramento, CA, 1999-2002

Fellowship, Gastroenterology & Hepatology, University of Maryland School of Medicine / National Institute of Diabetes and Digestive and Kidney Diseases, NIH, 2006-2009

Biosketch

Dr. von Rosenvinge graduated Phi Beta Kappa from the University of Maryland at College Park in 1995 with a degree in Biochemistry. He then attended the New York University School of Medicine, where he was elected to the Alpha Omega Alpha honor society. After graduating in 1999, he completed his residency training in Internal Medicine in a combined program at the David Grant USAF Medical Center, Travis AFB, California; and the UC Davis Medical Center in Sacramento, California. 

Dr. von Rosenvinge served as a Staff Physician in the US Air Force from 2002 to 2006. During this time he also served as an Assistant Professor at the F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, and was deployed twice in support of Operations Iraqi Freedom and Enduring Freedom, earning him numerous military honors. After finishing his military service, Dr. von Rosenvinge completed his fellowship training in Gastroenterology & Hepatology at the University of Maryland School of Medicine, Baltimore, and the National Institutes of Health, Bethesda, Maryland. Dr. von Rosenvinge joined the faculty of the University of Maryland School of Medicine and Baltimore VA Medical Center in July 2009.

Dr. von Rosenvinge's research and clinical interests include Clostridium difficile infection, the gastrointestinal microbiome, fecal microbiota transplantation, and improving colorectal cancer screening. 

Research/Clinical Keywords

Clostridium difficile, gastrointestinal microbiome, fecal microbiota transplantation, colorectal cancer

Highlighted Publications

von Rosenvinge EC, Sang Y, White JR, Maddox C, Blanchard T, Fricke WF. Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota. ISME Journal. 2013 Jul;7(7):1354-66.

von Rosenvinge EC, Cheng K, Drachenberg CB, Fowler CB, Evers DL, Xie G, Raufman JP. Bedside to bench: Role of muscarinic receptor activation in ultrarapid growth of colorectal cancer in a patient with pheochromocytoma. Mayo Clinic Proceedings. 2013 Nov;88(11):1340-46.

Song Y, Garg S, Girotra M, Maddox C, von Rosenvinge EC, Dutta A, Dutta S, Fricke WF. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection. PLOS ONE. 2013 Nov;8(11):e81330.

Yu H, Chen K, Wu J, Yang Z, Shi L, Barlow LL, Aronoff DM, Garey KW, Savidge TC, von Rosenvinge EC, Kelly CP, Feng H. Identification of toxemia in patients with Clostridium difficile infection. PLOS ONE2015 Apr 17;10(4):e0124235.

Maldarelli GA, Piepenbrink KH, Scott AJ, Freiberg JA, Song Y, Achermann Y, Ernst RK, Shirtliff ME, Sundberg EJ, Donnenberg MS, von Rosenvinge EC. Type IV pili promote early biofilm formation by Clostridium difficile. Pathogens and Disease. 2016 Aug;74(6).